Lonza to Divest Specialty Ingredients Business to Bain Capital and Cinven for $4.7B

 Lonza to Divest Specialty Ingredients Business to Bain Capital and Cinven for $4.7B

Lonza to Divest Specialty Ingredients Business to Bain Capital and Cinven for $4.7B

Shots:

  • Bain Capital and Cinven to acquire Lonza’s specialty ingredients business and operations for an enterprise value of $4.7B. The transaction is expected to close in H2’21
  • The divestiture will allow Lonza to refocus its business as a pure-play partner to the healthcare industry
  • Lonza’s specialty ingredients business provides microbial control solutions for Professional Hygiene and Personal Care products and offers the custom development and manufacturing of specialty chemicals and composites to support the electronics, aerospace, food and agrochemical industries

Click here ­to­ read full press release/ article | Ref: Lonza | Image: 24 News Update Blog

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post